Sugi Predict

Sugi Predict / Compounds / SCHEMBL4620775

SCHEMBL4620775

SCHEMBL4620775

O=C1Cc2ccc(I)cc2N1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP2 O95551 4/20 0.62
▸ AHR P35869 4/20 0.61
▸ CMA1 P23946 2/20 0.61
▸ EIF2AK2 P19525 1/20 0.59
▸ PDK2 Q15119 1/20 0.53
▸ CRBN Q96SW2 3/20 0.46
▸ CCNB2 O95067 2/20 0.43
▸ CDK1 P06493 2/20 0.43
▸ CCNB1 P14635 2/20 0.43
▸ GSK3B P49841 2/20 0.43
▸ CDK5 Q00535 2/20 0.43
▸ CDK5R1 Q15078 2/20 0.43
▸ CCNB3 Q8WWL7 2/20 0.43
▸ PDE3B Q13370 1/20 0.42
▸ PDE3A Q14432 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ SMYD3 Q9H7B4 1/20 0.41
▸ EPHX2 P34913 1/20 0.40
▸ TGM2 P21980 1/20 0.40
▸ CES1 P23141 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1459491 0.84 TDP2 (0.62) TDP2AHRCMA1EIF2AK2PDK2
SCHEMBL2616856 0.82 CA9 (0.62) TDP2CRBNCA9SMYD3
SCHEMBL9025047 0.79 MAPT (0.58) TDP2AHRCMA1EIF2AK2CRBN
SCHEMBL3575463 0.77 TDP2 (1.00) TDP2
SCHEMBL18010828 0.77 TDP2 (1.00) TDP2
Formic Acid SCHEMBL30925701 0.77 TDP2 (0.54) TDP2AHRCMA1EIF2AK2PDK2
SCHEMBL1833499 0.76 AHR (0.61) TDP2AHRCMA1EIF2AK2PDK2
SCHEMBL278958 0.76 AHR (0.61) AHRCMA1EIF2AK2PDK2CRBN
SCHEMBL19042841 0.76 AHR (0.61) TDP2AHRCMA1EIF2AK2PDK2
SCHEMBL1046966 0.76 AHR (0.61) TDP2AHRCMA1EIF2AK2PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2892873-A1 PROCESS FOR PREPARING 6-IODO-2-OXINDOLE Boehringer Ingelheim International GmbH (DE) 2015-07-15 — — EP claimed
US-8975418-B2 Process for preparing 6-iodo-2-oxindole BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-03-10 — — US claimed
WO-2014037307-A1 PROCESS FOR PREPARING 6-IODO-2-OXINDOLE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-03-13 — — WO claimed
US-20140066634-A1 PROCESS FOR PREPARING 6-IODO-2-OXINDOLE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-03-06 — — US claimed
US-20140018372-A1 CRYSTALLINE FORM OF A INDOLINONE DERIVATIVE AND ITS USE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-16 — — US claimed
WO-2014009318-A1 3-{3-[1 -(4-DIMETHYLAMINOMETHYL-PHENYLAMINO)-1 -PHENYL-METH-(Z)-YLIDENE]-2-OXO-2,3-DIHYDRO-1 H-INDOL-6-YLL-PROPYNOIC ACID ETHYLAMIDE AND ITS USE IN THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-16 — — WO claimed
WO-2025233641-A1 NOVEL PHOTOINDUCIBLE KINASE INHIBITORS FOR TREATING PROLIFERATIVE AND VASOPROLIFERATIVE DISEASES SEMMELWEIS EGYETEM (HU) 2025-11-13 — — WO disclosed
WO-2023098880-A1 FUSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 上海翰森生物医药科技有限公司 2023-06-08 — — WO disclosed
WO-2020207352-A1 TRIAZINE BENZIMIDAZOLE COMPOUNDS AND MEDICAL USE THEREOF 四川科伦博泰生物医药股份有限公司 2020-10-15 — — WO disclosed
US-9873693-B2 Methods of treatment using pyridinonyl PDK1 inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2018-01-23 — — US disclosed
EP-2892873-A1 PROCESS FOR PREPARING 6-IODO-2-OXINDOLE Boehringer Ingelheim International GmbH (DE) 2015-07-15 — — EP disclosed
EP-2892873-A1 PROCESS FOR PREPARING 6-IODO-2-OXINDOLE Boehringer Ingelheim International GmbH (DE) 2015-07-15 — — EP disclosed
EP-2872501-A1 PYRIMIDINE PYRAZOLYL DERIVATIVES Ares Trading S.A. (CH) 2015-05-20 — — EP disclosed
EP-1945632-A1 HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals Incorporated (US) 2008-07-23 — — EP disclosed
EP-1902024-A2 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 — — EP disclosed
WO-2007056341-A1 HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-05-18 — — WO disclosed
US-20070015748-A1 Kinase Inhibitors ALLERGAN, INC. 2007-01-18 — — US disclosed
US-20070015748-A1 Kinase Inhibitors ALLERGAN, INC. 2007-01-18 — — US disclosed
US-20070015748-A1 Kinase Inhibitors ALLERGAN, INC. 2007-01-18 — — US disclosed
WO-2007008985-A2 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018372-A1 CRYSTALLINE FORM OF A INDOLINONE DERIVATIVE AND ITS USE PIR, IDO1, UACA TDP2 1259/4885AHR 1057/4885CMA1 2918/4885
US-20140066634-A1 PROCESS FOR PREPARING 6-IODO-2-OXINDOLE INTS6, IP6K2, CYP2D6 TDP2 2030/4885AHR 1509/4885CMA1 1126/4885
US-20070015748-A1 Kinase Inhibitors ABL1, LCK, ERBB2 TDP2 1276/4885AHR 2478/4885CMA1 2860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.